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Abstract
Background: Most microarray data processing methods negate extreme expression values or
alter them so that they do not lie outside the mean level of variation of the system. While
microarrays generate a substantial amount of false positive and spurious results, some of the
extreme expression values may be valid and could represent true biological findings.
Methods: We propose a simple method to screen brain microarray data to detect individual
differences across a psychiatric sample set. We demonstrate in two different samples how this
method can be applied.
Results: This method targets high-throughput technology to psychiatric research on a subject-
specific basis.
Conclusion: Assessing microarray data for both mean group effects and individual effects can lead
to more robust findings in psychiatric genetics.
Background
Currently used psychiatric nosology is based on a compi-
lation of clinical symptoms into categories based prima-
rily on symptom clustering and course. Diagnostic
systems such as the current version of the DSM, allow for
certain flexibility in the definition of diagnostic catego-
ries, with no assumption that each category of mental dis-
order is a completely discrete entity. As such, individuals
diagnosed under a certain diagnostic class are not clini-
cally homogeneous, there are no clear boundaries
between classes, and different classes are not mutually
exclusive. It is, therefore, unrealistic to expect that all sub-
jects diagnosed with a given disorder will share a common
psychopathological process, which would be associated
with a common underlying biological process.
Most research efforts in psychiatry are directed towards
the identification of group effects, negating the fact that
significant etiological heterogeneity may exist. This limita-
tion is particularly true for microarray research in psychi-
atry, where gene expression from different brain areas has
been assessed comparing all affected subjects to non-
affected subjects. A possible solution would be to carry
out studies aiming at the identification of biologically
meaningful effects focusing on single individuals or sub-
groups. This approach would mimic fruitful efforts in the
identification of genetic factors underlying heterogeneous
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conditions such as, among others, spinocerebellar ataxia
[1] and Alzheimer's disease [2].
Microarray data from psychiatric subjects can be investi-
gated for individual or subgroup effects that may be of
genuine biological significance. Specifically, we hypothe-
size that specific subgroups can be identified through
microarray data screening for extreme expression values.
Three previous studies have described how microarray
data can be investigated on a subject-specific basis when
analyzing data from cancer studies [3-5]. We suggest here
that microarray experiments using brain-gene expression
levels from psychiatric experiments (e.g. schizophrenia
group vs non- schizophrenia group) can utilize microar-
ray data not only for group mean effects (i.e. standard
microarray analysis) but also, whenever possible, should
evaluate expression levels by individual subjects.
Most microarray projects in psychiatry involve examining
more than one neural region [6-9]. Specifically, research-
ers studying gene expression in brain tend to analyze
more than one brain region on more than one array. This
leaves researchers with gene expression data from multi-
ple brain regions for each subject. This offers the possibil-
ity of using data from different arrays as confirmations of
findings which may appear to be outliers. Any outlier on
one chip that is also an outlier on a different chip may rep-
resent a valid finding.
Human brain has been categorized in two main ways:
either by gross anatomical structure, the preference of
imaging specialists, or by Brodmann region, the prefer-
ence of neuro-anatomists. Irrespective of how the human
brain is categorized anatomically, what is less obvious is
whether gene expression varies between neighboring
regions. Two recent, replicating studies suggest that brain
gene expression of samples from the same individual,
while non-identical, are biologically-related [9,10]. This
sharing of similar expression patterns across samples
allows for the exclusion of extreme values in the microar-
ray data due to noise. This provides a potential to validate
microarray data, particularly for variables that are extreme
values, across chips. Those extreme values present across
chips for the same probe set and the same individual may
represent a true biological effect.
We have designed a method that can assess extreme values
and utilizes expression data across chips from the same
individual. The method will allow for the detection of any
subjects that have probe set values that differ drastically
from a mean and outside of a certain threshold (e.g.
Standard deviations from a mean). This method, termed
Extreme Values Analysis (EVA), takes into account the
complex and heterogeneous nature of psychiatric dis-
eases. We illustrate this approach in two different situa-
tions. First, in a publicly available sample where extreme
values were simulated, and second, in a sample of subjects
who died by suicide and sudden death controls. EVA func-
tions to screen microarray data individual-by-individual
in search for any extreme values that may signify some
abnormality.
Methods
We used a publicly available data set to first evaluate EVA.
The data set comprises 9 subjects screened over 20 regions
of the CNS and can be found here [9]. In this dataset, one
of the authors (AB) inputted simulated extreme values for
two subjects across all CNS regions for one randomly
selected probe set each. The expression values were multi-
plied by 4(1+0.25Z)  for one of the probe sets and by
0.25(1+0.25Z) for the other, where Z is a standard normal
random variable which was generated independently for
each CNS region. Another of the authors (CE), blinded to
the experimental manipulation, applied the method to
detect the inputted value(s). The rationale for this experi-
ment is to determine if EVA can detect an artificially gen-
erated extreme value in one probe set from > 11 million
different data points (10 subjects X 20 regions X~55,000
probe sets).
We assessed EVA in a second sample that comprised a
group of suicide completers and sudden death controls.
Information on the subjects, clinical variables, and micro-
array data quality of the suicide and sudden death con-
trols can be found in Sequeira et al.,[6].
EVA can be applied under a control:experimental design
(suicide and sudden death controls example) or in a one
sample design (CNS screening example). We describe the
control:experimental setting, although the description
applies also to the one sample design. In the one sample
design, all individual values are compared to the group to
which they belong.
The mean and standard deviation (SD) of log2-trans-
formed expression level is computed in the experimental
group for all probe sets in every region. In our example,
this was done in 2 cortical brain regions from suicide sub-
jects. Log transformation stabilizes the variance, allowing
comparison of SD across probe sets. After this step, the
probe sets with the highest SD values were selected for fur-
ther analysis. We used only those probe sets in the top 5%
of SD values. We reasoned that these probe sets likely have
individual values that are extreme, which accounts for a
high SD value.
To buffer against detecting mathematical artifacts, EVA
selects only those probe sets with high SD values in all
regions. In our example, we selected probe sets that were
common across both cortical regions. Next, we assessBMC Psychiatry 2008, 8:29 http://www.biomedcentral.com/1471-244X/8/29
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whether the same subject is responsible for the high SD
value across brain regions. We set as criterion for an
extreme expression a value of ± 3 fold greater than the
mean expression level of the specific probe set among the
control group (in our example, the sudden death con-
trols). This approach operates on the assumption that
neighboring brain regions are not discrete units and that
gene expression should not vary widely from one cortical
region to another. Even if brain region-specific expression
is more common, it is not expected that a subject that is
an outlier in one region is necessarily an outlier in a neigh-
boring region. In other words, extreme values that are
detected across multiple brain regions are more likely to
represent real biological phenomena. We note that this
method is conservative.
Individual expression values also have to be outside of 1.5
SD's of the control group, after having met the above cri-
teria. While we selected 1.5 SD's from the mean of the
opposite group, this number can be changed depending
on the false discovery level acceptable to the experi-
menter. Manipulating the SD threshold establishes the
false discovery rate (FDR) of the experiment.
The statistical significance of each identified outlier can be
assessed by computing the p-value of the subject's expres-
sion values for a probe set in the multiple brain regions
compared to the multivariate distribution of the expres-
sion values in the control group. The null distribution of
the log2-transformed probe set-specific expression is esti-
mated by fitting a normal mixed model where the subject
effect is random. Letting, Xij  be the probe set-specific
expression of the ith subject in the jth brain region, and Yij
= log2(Xij), this model has the form:
Yij = μj + ai + eij, ai~N(0,τ2), eij~N(0,σ2)
where μj is the region-specific mean expression, ai is the
subject random effect and eij is the residual. We fit such a
model by restricted maximum likelihood (REML) using
the maanova package [11] for the R statistical software
[12]. The subject random effect captures the expected cor-
relation between expression in different brain regions of
the same subject. The p-value for the observed deviation
of the log2-transformed expression level of the ith subject
from the mean of the group of reference  , j = 1,..., J (or
observed fold change on the original scale) is given by
which we compute using a multivariate t-distribution
with the covariance matrix estimated under the normal
mixed model.
Results
EVA in partially simulated data
We tested EVA in a sample data set that included 20 differ-
ent CNS regions [9]. This dataset was selected because A)
we could test how the method works with the RMA algo-
rithm and B) we could demonstrate the method in a one-
sample case.
We began by computing the standard deviation (SD) for
three of the 20 CNS regions described in this data set. The
probe sets in the top 5% of SD values was selected for each
of three regions and those probe sets that were common
to all regions were selected. Five hundred forty-five probe
sets were common to all three regions. Next, we screened
for any individual values that lay outside of ± 1.5 SD's and
was three-fold different from the mean. There were 14
genes that were found to be 3-fold greater than the mean
and outside of +1.5SD's and 245 values that were three
fold below the mean and outside of -1.5SDs. Each of these
values was then cross-referenced across all 20 CNS
regions. Two probe sets were found that met all criteria (1
above the mean for one subject and one below the mean
for another subject). These were the probe sets that had
been artificially altered (Figure 1).
EVA in real microarray data
To demonstrate this technique, we used a sample that
included 6 control subjects and 8 suicide completers with
microarray data from BA 8/9 and BA 11. We first screened
all expression values for MAS 5.0 present/absent call leav-
ing 14,896 probe sets in BA 8/9 and 14,412 probe sets in
BA 11. We next calculated a standard deviation for all
probe sets from suicide subjects. This was done using log2-
transformed expression values. We then selected the
probe sets with the highest SD values (top 5%) from both
BA 8/9 and BA11.
Any probe sets that was identical to both BA 8/9 and BA
11 after SD filtering was selected. There were 180 probe
sets that were common to both regions. Next, to account
for the variability of expression in control values, we
searched the data for any suicide data point greater than
3-fold from the control mean and outside of 1.5 SD's. We
reasoned that an extreme value across all regions for the
same subject(s) could represent a biologically relevant
event.
Beginning in BA 8/9, we filtered the 180 probe sets for
those probe sets from suicide completers outside of 3-fold
from the control mean. There were 20 probe sets where Xij
(a particular expression value from a particular subject in
a given brain region) was not outside of 3-fold from the
control mean. From the 160 remaining probe sets, 108
probe sets were also outside of 1.5 SD's in BA 8/9. Probe
sets from BA 11 were then filtered for these probe sets.
ˆ μj
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Microarray expression values demonstrating two subjects who passed all EVA criteria in a one sample case Figure 1
Microarray expression values demonstrating two subjects who passed all EVA criteria in a one sample case. A) 
Extreme low expressor (light blue trace) compared to other subjects in the same sample for one probe set identified across 
multiple CNS regions. Each subject is represented by a letter (A, B, C...). B) Extreme high expressor (purple trace) compared 
to other subjects in the same sample for one probe set across multiple CNS regions.BMC Psychiatry 2008, 8:29 http://www.biomedcentral.com/1471-244X/8/29
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Table 1: HG-U133 plus 2 probe sets that met all EVA criteria. Numbers represent p-values generated for each probe set across each 
subject (S). Subjects who met EVA criteria have p-values underlined. Note that p-values are generated from the number of SD's from 
the mean, therefore some subjects with very small p-values may be outside of a given number of SD's but < 3-fold different than the 
mean.
P r o b e  s e t S 1S 2S 3S 4S 5S 6S 7S 8
233814_at 0.00011 0.262901 0.060973 0.119425 0.340339 0.065993 0.291037 0.044823
225440_at 0.003777 0.041856 0.549775 0.617546 0.000754 0.044895 0.52789 0.000355
203638_s_at 0.008775 0.076607 0.099598 0.154338 0.000159 0.089298 0.01575 0.357839
214680_at 2.89E-05 0.010459 0.007155 0.001488 0.00034 0.007818 0.000768 0.148031
37170_at 0.001734 0.002016 0.095708 0.010663 0.000198 0.000259 0.003458 0.140702
227556_at 0.00074 0.397533 0.000597 0.010661 0.291994 7.80E-07 0.100161 0.010813
229917_at 0.00895 0.170125 0.421083 0.044559 0.401754 0.000248 0.055834 0.003505
227330_x_at 0.018916 0.412934 0.378829 0.053889 0.002547 0.576196 0.037467 0.46594
231804_at 0.411319 0.07522 0.566597 0.115634 0.485137 0.489949 0.28554 0.012676
200904_at 0.066736 0.080689 0.236431 0.504115 0.009175 0.255437 0.466512 0.105319
230141_at 0.041214 0.157873 0.408831 0.09835 0.013597 0.067947 0.333108 0.004167
222020_s_at 6.92E-05 0.071294 0.239087 0.018151 0.271669 0.043433 0.044077 0.428814
213812_s_at 0.004793 0.002408 0.151259 0.121657 0.15422 0.030286 0.022571 0.02784
201505_at 0.316616 0.570798 0.160905 0.60401 0.000337 0.19324 0.157064 0.00128
240467_at 0.103838 0.007113 0.076142 0.001703 0.050236 0.332126 0.148029 0.199109
229861_at 0.005266 0.047216 0.055746 0.000202 0.028745 0.028233 0.019457 0.00037
225872_at 0.001483 0.528714 0.628325 0.427906 0.000266 0.396505 0.019428 0.194352
241758_at 0.625246 0.629225 0.435153 0.452194 0.005473 0.282962 0.223662 0.001718
214449_s_at 0.400041 0.272717 0.30737 0.020469 0.000229 0.040009 0.340049 0.000813
200648_s_at 0.011284 0.10939 0.371707 0.02763 0.013746 0.07564 0.02506 0.264293
221795_at 0.000617 0.006302 0.070084 0.008107 0.005545 0.039509 0.01825 0.284639
204379_s_at 0.046084 0.083475 0.391619 0.237209 0.025689 0.079905 0.073448 0.22916
215172_at 0.109908 0.139031 0.199485 0.152187 0.155703 0.203207 0.144057 0.001802
203324_s_at 0.005691 0.092966 0.150765 0.000126 0.00021 0.056637 0.205541 0.183977
202800__at 0.077088 0.491247 0.411825 0.162812 0.013449 0.102756 0.028244 0.452363
236223_s_at 0.030208 0.196886 0.209618 0.000686 0.25837 0.13088 0.373756 0.268783
209023_s_at 5.10E-05 0.000708 0.030401 0.001934 0.251739 0.002706 2.10E-05 0.054205
213593_s_at 0.005575 0.001263 0.108932 0.005416 0.007774 0.20946 0.083709 0.036244
222249_at 0.101364 0.131587 0.040535 0.007024 0.009912 0.096597 0.00014 0.012586
220460_at 0.018979 0.539318 0.195645 0.120094 0.009469 0.067115 0.013541 0.346847
201656_at 0.000481 0.13031 0.064596 0.010041 0.000455 0.018925 0.14539 0.117989
235775_at 0.000373 0.079169 0.040214 0.11224 0.000676 0.222721 0.208163 0.049906
204516_at 9.40E-05 0.051213 0.096458 0.027735 0.003274 0.277745 0.208683 0.17238
201843_s_at 0.047846 0.096131 0.228376 0.016614 0.010238 0.104263 0.005888 0.155651
204712_at 0.024623 0.417385 0.556647 0.127233 0.010306 0.182687 0.121824 0.39341
224736_at 0.002159 0.02277 0.118888 0.114733 0.126571 0.333625 0.187404 0.021966
214203_s_at 0.018997 0.038021 0.062828 0.074293 0.00133 0.017613 0.003911 0.047244
200914_x_at 0.010589 0.005141 0.075284 0.058115 0.042784 0.274358 0.103149 0.103501
222404_x_at 0.003613 0.040237 0.059019 0.220239 0.151453 0.188272 0.358947 0.103866
229553_at 0.008515 0.022552 0.02734 0.070236 0.14418 0.145378 0.331622 0.223119
203249_at 0.139981 0.138389 0.229283 0.100477 0.004921 0.094854 0.07573 0.002453
203041_s_at 0.01742 0.111182 0.227792 0.402694 0.014214 0.310238 0.14055 0.174457
209292_at 0.068175 0.345992 0.507253 0.01934 0.006611 0.099673 0.002438 0.275859
226084_at 0.00373 0.005272 0.059754 0.096792 0.076702 0.642227 0.101137 0.153124
204976_s_at 0.00165 0.083667 0.100336 0.152992 0.00468 0.159244 0.449992 0.583733
212368_at 0.013283 0.016864 0.07334 0.086183 0.13413 0.246171 0.126799 0.293217
211962_s_at 0.00228 0.17037 0.178376 0.026324 0.0011 0.017557 0.011854 0.278736
226228_at 0.090147 0.423425 0.572415 0.125902 0.015242 0.100574 0.077677 0.633229
213954_at 0.002753 0.001918 0.022841 0.013454 8.47E-05 0.018911 0.075725 0.077512
213922_at 0.004719 0.003408 0.109555 0.024766 0.07629 0.417034 0.042621 0.199903
221517_s_at 0.001167 0.00413 0.048293 0.022654 0.003271 0.150882 0.080039 0.011072
227099_s_at 0.047549 0.092241 0.069821 0.333917 0.000425 0.00361 0.200933 0.009189
201737_s_at 0.000159 0.012972 0.219393 0.110936 0.092836 0.273891 0.078928 0.035264
214279_s_at 0.008594 0.363441 0.365898 0.01142 0.036218 0.014181 0.059127 0.066575
205709_s_at 0.007059 0.021998 0.110402 0.359529 0.08021 0.218438 0.306235 0.206374
225810_at 0.039054 0.256396 0.159142 0.452173 0.001525 0.010676 0.017581 0.130546
226435_at 0.150996 0.248593 0.432525 0.004589 0.032368 0.12243 0.072016 0.216067BMC Psychiatry 2008, 8:29 http://www.biomedcentral.com/1471-244X/8/29
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Table 1 lists the probe sets across the eight suicide compl-
eters and the individual p-values associated with each sub-
ject. From 108 probe sets that passed all EVA criteria in BA
8/9, 69 passed all EVA criteria in BA 11. Included in this
list of probe sets are a number of genes that have been
linked to suicide before including the FGF family [13],
NTRK2 [14], and members of the ubiquitin family [15].
Of note, from the table, is that for a number of probe sets
there is more than one subject who has an extreme expres-
sion value reaching a significance level.
Discussion
The extreme values analysis, or EVA, is a method to detect
individual or subsets of outliers for a given probe set in
microarray experiments. The rationale for this type of
experiment is that psychopathology is not necessarily
group specific but more likely sub-group or subject spe-
cific. The method outlined here uses log-transformed data
to determine which probe sets have the highest variance
and screens out those probe sets with little variation. This
step is intended to select those probe sets with values that
deviate widely from the mean. Next the method compares
individual data points to a control mean, and searches for
any 3-fold changes. Selected values also have to be outside
of 1.5 SD's from the mean. These values were considered
extreme expression values. These extreme expression val-
ues were next verified in one other cortical region to deter-
mine if they were extreme expression values in other
cortical regions as well. We reasoned that the use of other
cortical regions functioned as replicate experiments and
enforced the finding.
We also evaluated this method in a one sample case after
inputting artificial values for one probe set across all CNS
regions in RMA data. EVA was able to detect the inputted
value; the only difference between the control:experimen-
tal case and one sample case is the mean value used: In the
one sample case the mean used includes the extreme value
while in the control:experimental case it does not.
The use of multiple cortical regions as within-subject rep-
licates is a way to detect true extreme expression values in
individual subjects. Operating under the assumption the
gene expression in one cortical region is generally similar
in neighboring cortical regions, we propose that different
chips for the same subject can be used as replicate experi-
ments, if probe set outliers on an individual specific basis
are being investigated. If an observed outlier is a real bio-
logical event, it is very probable that the same subject on
the same probe set will also be an outlier in a neighboring
region. Consider, for example, the family with a deletion
in the MAOA gene [16]. Had this family undergone post-
mortem microarray analysis as a part of a larger sample of
subjects, EVA would have detected the MAOA decrease in
expression whereas microarray analysis using mean group
effects would not have. Using multiple brain regions as
replicates does undermine the idea that gene expression is
different across different brain regions, which it is [10,17];
however, it means that if an effect is detected, it is likely
real and robust.
Comparison to PPST method
The PPST method [5] counts the number of subjects in
both control and experimental group outside of the 95th
percentile of the opposite group. The FDR is therefore
controlled by altering the percentile threshold. EVA uses
the SD from the opposite group and counts the number of
subjects that are outside a given SD value (± 1.5 SDs in
this study). Selecting more stringent SD values allows for
direct manipulation of the FDR. In this study a liberal cut-
off was chosen (outside of 1.5SD's). The FDR among the
detected outliers could be estimated from the p-value of
the subject's expression values using standard methods
such as that of Reiner et al. [18]
Comparison to COPA method
Cancer outlier profile analysis (COPA) is another outlier
detection that has proved fruitful in the past[4]. This tech-
nique normalizes all probe sets (one sample design) and
226364_at 0.310524 0.026062 0.011704 0.02649 0.026889 0.178983 0.048683 0.005222
240482_at 0.318335 0.475263 0.195512 0.214718 0.151663 0.390872 0.003578 0.001316
204881_s_at 0.00017 0.068969 0.075294 0.117202 0.020759 0.039673 0.310769 0.084319
203841_x_at 0.000201 0.005823 0.089297 0.006843 0.052791 0.114169 0.037911 0.052824
212677_s_at 0.021412 0.003193 0.033988 0.022312 0.03778 0.128097 0.090665 0.060285
201502_s_at 0.001372 0.006379 0.167335 0.041531 0.035423 0.070657 0.263158 0.614172
240299_at 0.017658 0.276529 0.197699 0.008206 0.0622 0.215909 0.087937 0.025787
212423_at 0.024073 0.015847 0.140173 0.140948 0.19045 0.020469 0.19758 0.399876
228811_at 0.290584 0.349143 0.140068 0.371578 0.50686 0.002176 0.066324 0.002291
224737_x_at 0.000367 0.288851 0.112457 0.002641 0.097181 0.24341 0.219535 0.021662
201019_s_at 0.003446 0.00455 0.276132 0.181832 0.064501 0.680406 0.179361 0.099558
229281_at 0.090713 0.333165 0.42729 0.241316 0.000732 0.019187 0.025054 0.314121
Table 1: HG-U133 plus 2 probe sets that met all EVA criteria. Numbers represent p-values generated for each probe set across each 
subject (S). Subjects who met EVA criteria have p-values underlined. Note that p-values are generated from the number of SD's from 
the mean, therefore some subjects with very small p-values may be outside of a given number of SD's but < 3-fold different than the 
mean. (Continued)BMC Psychiatry 2008, 8:29 http://www.biomedcentral.com/1471-244X/8/29
Page 7 of 8
(page number not for citation purposes)
calculates the 75th, 90th, and 95th percentiles for each
probe set and rank-orders them by percentile score. A pri-
oritized list of probe set with some subjects that have
extreme expression values is then investigated. Tibshirani
and Hastie [3] introduce the outlier-sum statistic in their
paper to improve on the COPA method. Their method
differs from COPA by the standardization procedure of
each probe set expression level using the median and
median absolute deviation.
There are some caveats to be aware of before proceeding
with this approach to screen microarray data. Firstly, the
method is very conservative and likely has a high beta
error rate. It is very likely that there were a number of true
positives that were not detected because of the rigidity of
the design. Some parameters may need to be adjusted to
allow more probe sets to pass filtering (e.g. top 10% of SD
values instead of the top 5% being used). Second, this
method has the disadvantage of requiring a number of
replicates per individual, a component that could be cost-
prohibitive. Third, the method can only be used to study
genes whose expression levels are similar across brain
regions. Finally, we note that all probe-level microarray
algorithms dampen extreme values at the scanner. This
method is conservative and could only be used to investi-
gate extreme values after initial processing.
Our view for this technique is as another analysis tech-
nique to further explore microarray data, in conjunction
with more mainstream techniques [19]. This method,
termed Extreme Values Analysis, can detect extreme differ-
ences in gene expression on a subject-by-subject basis
from microarray data across different chips. The method
uses high-throughput technology in a non-biased way to
understand psychiatric disease for each subject investi-
gated.
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